We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+41.63%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.37B
AUM Growth
+$500M
Cap. Flow
+$109M
Cap. Flow %
4.61%
Top 10 Hldgs %
58.56%
Holding
56
New
7
Increased
13
Reduced
6
Closed
6

Top Buys

1
CGON icon
CG Oncology
CGON
+$31.4M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$23.8M
3
BBIO icon
BridgeBio Pharma
BBIO
+$23.5M
4
SLNO
Soleno Therapeutics
SLNO
+$18.6M
5
PEPG icon
PepGen
PEPG
+$17.7M

Top Sells

1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.1M
2
DYN icon
Dyne Therapeutics
DYN
+$15.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.1M
4
APGE icon
Apogee Therapeutics
APGE
+$11.2M
5
ETNB
89bio
ETNB
+$11.1M

Sector Composition

1 Healthcare 99.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
26
Structure Therapeutics
GPCR
$3.44B
$27M 1.14%
629,194
+312,004
+98% +$13.2M
TRVI icon
27
Trevi Therapeutics
TRVI
$2.82B
$25.5M 1.07%
7,381,090
– –
SLN
28
Silence Therapeutics
SLN
$517M
$24.8M 1.05%
1,148,591
+267,418
+30% +$5.81M
DCPH
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$22.9M 0.97%
1,455,837
+434,037
+42% +$6.68M
PEPG icon
30
PepGen
PEPG
$156M
$22.1M 0.93%
+1,502,788
New +$17.7M
ANAB icon
31
AnaptysBio
ANAB
$1.66B
$20.3M 0.85%
899,700
– –
SVRA icon
32
Savara
SVRA
$1.14B
$19.9M 0.84%
4,000,000
– –
CERE
33
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$16.6M 0.7%
393,000
– –
AGIO icon
34
Agios Pharmaceuticals
AGIO
$2.34B
$15.3M 0.65%
523,166
– –
ADVM
35
DELISTED
Adverum Biotechnologies
ADVM
$15.1M 0.64%
+1,069,244
New +$16.3M
PBYI icon
36
Puma Biotechnology
PBYI
$436M
$14.9M 0.63%
+2,816,294
New +$15.2M
TYRA icon
37
Tyra Biosciences
TYRA
$1.96B
$13.6M 0.58%
832,220
-194,200
-19% -$3.19M
APLT
38
DELISTED
Applied Therapeutics
APLT
$13.3M 0.56%
+1,952,857
New +$8.77M
ALLO icon
39
Allogene Therapeutics
ALLO
$625M
$12.8M 0.54%
+2,867,750
New +$12M
ARVN icon
40
Arvinas
ARVN
$525M
$11.8M 0.5%
285,331
– –
ETNB
41
DELISTED
89bio
ETNB
$11.6M 0.49%
1,000,000
-1,000,000
-50% -$11.1M
ACAD icon
42
Acadia Pharmaceuticals
ACAD
$4.39B
$8.7M 0.37%
470,338
-260,579
-36% -$6.46M
COGT icon
43
Cogent Biosciences
COGT
$6.68B
$6.29M 0.27%
936,576
-1,058,691
-53% -$6.54M
NTLA icon
44
Intellia Therapeutics
NTLA
$1.64B
$5.6M 0.24%
203,684
– –
NAMSW icon
45
NewAmsterdam Pharma Warrant
NAMSW
$5.52M 0.23%
500,333
– –
ANTX icon
46
AN2 Therapeutics
ANTX
$167M
$4.51M 0.19%
1,388,889
– –
MGX icon
47
Metagenomi Therapeutics
MGX
$47.1M
$2.94M 0.12%
+279,025
New +$3.21M
GRTS
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.65M 0.11%
1,030,878
– –
BLUE
49
DELISTED
bluebird bio
BLUE
$2.19M 0.09%
85,495
– –
ACRS icon
50
Aclaris Therapeutics
ACRS
$768M
$328K 0.01%
264,377
– –
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2024 Portfolio in Review

As of Q1 2024, Frazier Life Sciences Management held 56 positions worth $2.37B, up 27% from $1.87B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Frazier Life Sciences Management deployed $109M of net new capital in Q1 2024, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was CG Oncology: 770,000 shares worth $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was 89bio, an estimated $11.1M trimmed.

  • Frazier Life Sciences Management's largest Q1 2024 buy was CG Oncology: 770,000 shares worth $33.8M.
  • Frazier Life Sciences Management added most to Oric Pharmaceuticals in Q1 2024, an estimated $23.8M increase.
  • Frazier Life Sciences Management's biggest Q1 2024 reduction was 89bio, cutting an estimated $11.1M.
  • Frazier Life Sciences Management fully exited Madrigal Pharmaceuticals in Q1 2024, selling an estimated $16.1M.
  • Frazier Life Sciences Management's ten largest holdings make up 59% of its $2.37B portfolio in Q1 2024.
  • Frazier Life Sciences Management opened 7 new positions and closed 6 in Q1 2024.
  • Frazier Life Sciences Management's portfolio value rose 27% quarter-over-quarter to $2.37B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2024, filed 15 May 2024.